On April the 20th, Teva Pharmaceutical Industries announced the launch of their new asthma inhaler, which will become the first direct competitor to Glaxo Smith and Kline’s Advair. Earlier this year, the company won approval in the United States to make an Advair alternative. Simultaneously, Teva launched a generic version of their AirDuo RespiClick. While Air Duo is not a true generic of Advair, it shares the same active ingredients, salmeterol and fluticasone propionate. The AirDuo will provide the user with a smaller dosage of salmeterol. At the same time, the inhaler utilizes Teva’s RespiClick. The company has decided to stick with their own inhaler rather than attempting to emulate GSK’s device.

During 2016, Advair generated around 2.35 billion dollars. While the inhaler is primarily used to treat asthma, it can also be administered to patients suffering from chronic obstructive pulmonary disease. AirDuo has only been approved for the treatment of asthma and cannot completely substitute Glaxo Smith and Kline’s Advair. Nevertheless, Teva’s generic alternative may very well be able to grab a significant share of the asthma market. Analyst Elliot Wilbur believes AirDuo could obtain as much as 25% of the market by the year 2018.

Glaxo Smith and Kline faces even stiffer competition. Several fully substitutable generic copies of Advair are currently awaiting approval. These generic inhalers have been produced by Hikma Pharmaceuticals and Vectura Group. These companies expect their inhalers to be approved by May the 10th. Mylan NV also produced a generic, but it was subsequently rejected in March. Glaxo Smith and Kline has been prepared for the launch of generics and the losses they’ll experience. Nevertheless, the blow will likely be swift and significant. More can be found at Reuters.

I am a proficient writer and news enthusiast. I strive to remain consistently up to date with the on-goings in the world, especially with businesses and markets.